JP2018520679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520679A5 JP2018520679A5 JP2017568207A JP2017568207A JP2018520679A5 JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5 JP 2017568207 A JP2017568207 A JP 2017568207A JP 2017568207 A JP2017568207 A JP 2017568207A JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- recombinant cell
- intracellular signaling
- protein
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 108091008042 inhibitory receptors Proteins 0.000 claims description 18
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims description 17
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims description 17
- 108091005703 transmembrane proteins Proteins 0.000 claims description 13
- 102000035160 transmembrane proteins Human genes 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186108P | 2015-06-29 | 2015-06-29 | |
| US62/186,108 | 2015-06-29 | ||
| PCT/US2016/040010 WO2017004150A1 (en) | 2015-06-29 | 2016-06-29 | Immune checkpoint chimeric antigen receptors therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520679A JP2018520679A (ja) | 2018-08-02 |
| JP2018520679A5 true JP2018520679A5 (cg-RX-API-DMAC7.html) | 2019-08-08 |
Family
ID=57609024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568207A Pending JP2018520679A (ja) | 2015-06-29 | 2016-06-29 | 免疫チェックポイントキメラ抗原受容体療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180185434A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3313892A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018520679A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180038447A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108137707A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016285859A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2991040A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1255637A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256643A (cg-RX-API-DMAC7.html) |
| MA (1) | MA42272A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018000278A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017004150A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| HK1222569A1 (zh) | 2013-09-17 | 2017-07-07 | Obi Pharma, Inc. | 用於诱导免疫反应的糖疫苗组合物及其治疗癌症的用途 |
| CA2948462A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
| CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| MA42902A (fr) * | 2015-07-08 | 2018-05-16 | Univ Johns Hopkins | Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car) |
| US10590169B2 (en) * | 2015-12-09 | 2020-03-17 | Virogin Biotech Canada Ltd | Compositions and methods for inhibiting CD279 interactions |
| ES2962588T3 (es) * | 2016-03-23 | 2024-03-20 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Proteínas de fusión de PD-1 y 4-1BB |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| TWI697333B (zh) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法 |
| JP2019527690A (ja) | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2019006852A (es) * | 2016-12-22 | 2019-08-26 | Windmil Therapeutics Inc | Composiciones y metodos para modular el sistema inmunologico. |
| KR102624509B1 (ko) | 2017-03-27 | 2024-01-12 | 싱가포르국립대학교 | 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주 |
| EP3600356A4 (en) | 2017-03-27 | 2020-12-23 | National University of Singapore | TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| CN112601758A (zh) | 2018-08-29 | 2021-04-02 | 新加坡国立大学 | 特异性刺激经基因修饰免疫细胞的存活和扩增的方法 |
| MX2021006399A (es) * | 2018-11-30 | 2021-07-15 | Windmil Therapeutics Inc | Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia. |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| WO2022098985A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Glioblastoma specific marrow infiltrating lymphocytes and uses thereof |
| TW202237177A (zh) * | 2020-11-19 | 2022-10-01 | 台灣浩鼎生技股份有限公司 | 通過globo 系列抗原的免疫調節之主動式癌症免疫療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201490364A1 (ru) * | 2011-07-29 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Костимулирующие рецепторы-переключатели |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| JP2016524464A (ja) | 2013-05-13 | 2016-08-18 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のために高活性ｔ細胞を操作するための方法 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3174546B1 (en) | 2014-07-31 | 2019-10-30 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| EP3922254A1 (en) | 2014-09-04 | 2021-12-15 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| EP3310805B1 (en) * | 2015-06-19 | 2021-02-17 | Kobold, Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
-
2016
- 2016-06-29 AU AU2016285859A patent/AU2016285859A1/en not_active Abandoned
- 2016-06-29 WO PCT/US2016/040010 patent/WO2017004150A1/en not_active Ceased
- 2016-06-29 MA MA042272A patent/MA42272A/fr unknown
- 2016-06-29 HK HK18114773.4A patent/HK1255637A1/zh unknown
- 2016-06-29 JP JP2017568207A patent/JP2018520679A/ja active Pending
- 2016-06-29 CA CA2991040A patent/CA2991040A1/en not_active Abandoned
- 2016-06-29 CN CN201680048831.3A patent/CN108137707A/zh active Pending
- 2016-06-29 KR KR1020187002679A patent/KR20180038447A/ko not_active Withdrawn
- 2016-06-29 EP EP16818647.6A patent/EP3313892A4/en not_active Withdrawn
- 2016-06-29 MX MX2018000278A patent/MX2018000278A/es unknown
- 2016-06-29 US US15/740,981 patent/US20180185434A1/en not_active Abandoned
- 2016-06-29 HK HK18113910.0A patent/HK1254820A1/zh unknown
-
2017
- 2017-12-28 IL IL256643A patent/IL256643A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520679A5 (cg-RX-API-DMAC7.html) | ||
| JP7026161B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| van Montfoort et al. | NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines | |
| Mitra et al. | Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps | |
| Prosser et al. | Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1: CD28 chimeric receptor | |
| Geller et al. | Use of allogeneic NK cells for cancer immunotherapy | |
| JP2017522862A5 (cg-RX-API-DMAC7.html) | ||
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| Barber et al. | Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma | |
| Sehgal et al. | Programmed death-1 checkpoint blockade in acute myeloid leukemia | |
| JP2016520074A5 (cg-RX-API-DMAC7.html) | ||
| JP2017515464A5 (cg-RX-API-DMAC7.html) | ||
| JP2020512284A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513478A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535292A5 (cg-RX-API-DMAC7.html) | ||
| JP2018029594A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508219A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522592A5 (cg-RX-API-DMAC7.html) | ||
| RS63574B1 (sr) | Metode za povećanje efikasnosti imuno ćelija | |
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2016534717A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518460A5 (cg-RX-API-DMAC7.html) | ||
| Tang et al. | CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo | |
| Merker et al. | Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children | |
| Tal et al. | An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities |